Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1565-1572

  Swain, S M ^a   Rowland, J ^a   Weinfurt, K ^a   Berg, C ^a   Lippman, M E ^a   Walton, L ^a   Egan, E ^a   King, D ^a   Spertus, I ^a   Honig, S F ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DISTRESS SYNDROME; DOSE RESPONSE; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

EID: 9244239744     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1565     Document Type: Article

References (29)

1. Nemoto T, Vana J, Bedwani RN, et al: Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45:2917-2924, 1980
2. Early Breast Cancer Trialists' Collaborative Group: The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
3. Hyrniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
4. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
5. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neulropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
6. Bronchud MH, Howell A, Crowther D, et al: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121-125, 1989
7. McNair DM, Lorr M, Droppleman LF: EdiTS Manual for the Profile of Mood States (revised). San Diego, CA, Educational and Industrial Testing Service, 1992
8. Cassileth BR, Lusk EJ, Brown LL, et al: Psychosocial status of cancer patients and next of kin: Normative data from the Profile of Moods States. J Psychosoc Oncol 3:99-105, 1985
9. Derogatis LR, Derogatis MF: The Psychosocial Adjustment to Illness Scale Administration, Scoring, and Procedures Manual-II. Tisane, MD, Clinical Psychometric Research Inc, 1990
10. Cella DF, Tulsky DS: Measuring quality of life today. Methodological aspects. Oncology 4:29-38, 1990
11. Weinstein MC: Cost-effective priorities for cancer prevention. Science 221:17-23, 1983
12. Gelber RD, Goldhirsch A: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772-1779, 1986
13. Priestman T, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1:899-901, April 24, 1976
14. Selby PJ, Chapman JAW, Etazadi-Amoli J, et al: The development of a method for assessing the quality of life of cancer patients. Br J Cancer 50:13-22, 1984
15. Cartell RB: Psychological measurement: Normative, ipsative, interactive. Psychol Rev 51:292-303, 1952
16. Stillwell TJ, Benson RC, Burgert EO: Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma. J Clin Oncol 6:76-82, 1988
17. Walther MM: Section 3 cystitis, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 2358-2362
18. Johnson WW, Meadows DC: Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N Engl J Med 284:290-294, 1971
19. Stillwell TJ, Benson RC: Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 61:451-457, 1988
20. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N Engl J Med 330:1253-1256, 1994
21. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22. Proc Am Soc Clin Oncol 13:64, 1994 (abstr)
22. DeCillis A, Anderson S, Wickerman DL, et al: Acute myeloid leukemia (AML) in NSABP B-25. Proc Am Soc Clin Oncol 14:98, 1995 (abstr)
23. Lichtman SM, Ratain MJ, Van Echo DA, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every two weeks: A Cancer and Leukemia Group B study. J Natl Cancer Inst 85:1319-1426, 1993
24. Yellen SB, Cella DF: Someone to live for: Social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13:1255-1264, 1995
25. Sutherland HJ, Lockwood GA, Cunningham AJ: A simple, rapid method of assessing psychological distress in cancer patients: Evidence of validity for linear analog scales. J Psychosoc Oncol 7:31-43, 1989
26. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
27. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
28. Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 6:1798-1810, 1988
29. Gotay CC, Korn EL, McCabe MS, et al: Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992